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Endotoxin, a bacterial lipopolysaccharide (LPS), causes fatal septic shock via Toll-like receptor 
(TLR)4 on effector cells of innate immunity like macrophages, where it activates nuclear 
factor 
 
 
 
B (NF-
 
 
 
B) and mitogen-activated protein (MAP) kinases to induce proinflammatory 
cytokines such as tumor necrosis factor (TNF)-
 
 
 
. Dok-1 and Dok-2 are adaptor proteins that 
negatively regulate Ras–Erk signaling downstream of protein tyrosine kinases (PTKs). Here, we 
demonstrate that LPS rapidly induced the tyrosine phosphorylation and adaptor function of 
these proteins. The stimulation with LPS of macrophages from mice lacking Dok-1 or Dok-2 
induced elevated Erk activation, but not the other MAP kinases or NF-
 
 
 
B, resulting in 
hyperproduction of TNF-
 
  
 
and nitric oxide. Furthermore, the mutant mice showed 
hyperproduction of TNF-
 
  
 
and hypersensitivity to LPS. However, macrophages from these 
mutant mice reacted normally to other pathogenic molecules, CpG oligodeoxynucleotides, 
poly(I:C) ribonucleotides, or Pam
 
3
 
CSK
 
4 
 
lipopeptide, which activated cognate TLRs but induced 
no tyrosine phosphorylation of Dok-1 or Dok-2. Forced expression of either adaptor, but not a 
mutant having a Tyr/Phe substitution, in macrophages inhibited LPS-induced Erk activation 
and TNF-
 
  
 
production. Thus, Dok-1 and Dok-2 are essential negative regulators downstream 
of TLR4, implying a novel PTK-dependent pathway in innate immunity.
 
The innate immune response to microbial
pathogens begins when pathogen-associated
molecular patterns (PAMPs) meet their cog-
nate receptors on effector cells. PAMPs are
conserved motifs on pathogens that are usually
not found in higher eukaryotes and include
LPS, a bacterial cell wall component and the
most potent stimulator in innate immunity (1).
Toll-like receptors (TLRs) recognize PAMPs,
and LPS stimulates the TLR4–MD-2 receptor
complex, which then triggers intracellular sig-
naling cascades (TLR4 signaling) including the
activation of NF-
 
 
 
B and three types of mitogen-
activated protein (MAP) kinases: Erk, JNK,
and p38 (2, 3). These signaling molecules play
indispensable roles in inducing TNF-
 
 
 
, a key
proinflammatory cytokine for innate immunity
(4). Recent studies have revealed that another
LPS receptor, CD14, facilitates the binding of
LPS to the TLR4–MD-2 complex and conse-
quent intracellular signaling (5). In addition,
TLR-mediated signaling depends upon adaptor
molecules such as MyD88 and Toll/IL-1 recep-
tor domain–containing adaptor-inducing IFN-
 
 
 
(TRIF) and is often classified into a MyD88-
or TRIF-dependent pathway. In fact, TLR4
triggers both pathways, and macrophages from
mice lacking these adaptors are defective in
proinflammatory responses to LPS (6).
Although the innate immune response is
essential for controlling the growth of patho-
genic microbes, negative regulation is also crit-
ical because excessive and unleashed responses
can cause inflammatory diseases such as septic
shock or chronic inflammation (4, 7–10). A Toll
IL-1 receptor family protein ST2 was recently
reported as an inducible negative regulator of
the MyD88-dependent pathway (7). Indeed,
mice lacking ST2 failed to develop endotoxin
tolerance a few days after primary administra-
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tion of a sublethal dose of LPS. However, due to the lag pe-
riod for its induction, ST2 appeared irrelevant to primary
endotoxin shock, a septic shock rapidly induced by LPS.
Gene targeting studies further revealed that IL-1 receptor–
associated kinase (IRAK)-M and suppressor of cytokine sig-
naling 1 are inducible negative regulators of LPS responses
(8–10). Despite these findings, very little is known about
constitutively expressed negative regulator(s) of TLR4 sig-
naling, which could work instantaneously upon LPS treat-
ment of macrophages to control the early phase of the sig-
naling and oppose endotoxin shock.
Dok-1 was originally identified as a major substrate of
many protein tyrosine kinases (PTKs; references 11–13).
When tyrosine phosphorylated, Dok-1 and its closest homo-
logue Dok-2 work as adaptor proteins and recruit multiple
SH2-containing molecules such as p120 rasGAP and Nck.
These adaptors are preferentially expressed in hematopoietic
cells and share structural similarities characterized by NH
 
2
 
-ter-
minal PH and PTB domains, followed by COOH-terminal
SH2 target motifs (11). Experiments with mice lacking Dok-1
or Dok-2 demonstrated an indispensable role in the negative
regulation of Erk downstream of PTKs in various hematopoi-
etic cells (14–16). However, mice lacking either adaptor did
not show overt defects in hematopoiesis. Although the bio-
logical significance of PTKs in TLR4 signaling is controver-
sial, LPS activates cytoplasmic PTKs including Lyn, which is
essential for the phosphorylation of Dok-1 upon B cell recep-
tor signaling (15, 17). Here, we have studied the role of Dok-1
and Dok-2 and demonstrate that these adaptors are constitu-
tively expressed negative regulators of TLR4 signaling.
 
RESULTS AND DISCUSSION
Dok-1 and Dok-2 are negative regulators of TNF-
 
  
 
and nitric oxide (NO) production upon LPS 
treatment of macrophages
 
To understand the role of Dok-1 and Dok-2 in TLR4 sig-
naling, we first examined the production of two major signal
mediators of innate immunity, TNF-
 
  
 
and NO, upon LPS
treatment of macrophages from mice lacking Dok-1 or
Dok-2. The peritoneal resident and BM-derived macro-
phages from either of the mutant mice showed a larger pop-
ulation of TNF-
 
 
 
–producing cells and greater NO produc-
tion than the wild-type cells, respectively (Fig. 1, A and B).
However, both mutant macrophages expressed normal levels
of LPS receptors, TLR4–MD-2, and CD14, indicating that
loss of Dok-1 or Dok-2 does not cause down-regulation of
these receptors (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20041817/DC1). Thus, Dok-1 and
Dok-2 are indispensable negative regulators of TNF-
 
  
 
and
NO production downstream of TLR4.
Figure 1. Dok-1 and Dok-2 are adaptors essential to the negative 
regulation of LPS responses. (A) Peritoneal resident macrophages from 
mice were treated with ( ) or without ( ) LPS, and then intracellular 
TNF-  production of CD11b  cells was examined with flow cytometry. 
(B) BM-derived macrophages were cultured in the indicated concentration 
of LPS and IFN- , and then NO production was evaluated. SD is from sex-
tuplicate experiments. (C) Dok-1 or Dok2 immunoprecipitates (IP) or whole 
cell lysates (WCL) were subjected to immunoblotting for Dok-1, Dok-2, 
phosphotyrosine (PY-Dok-1 or PY-Dok-2), or p120 rasGAP upon LPS treat-
ment of peritoneal macrophages for the indicated period. Position of 
immunoglobulin heavy chain (HC) is indicated. (D) Dok-1 immunoprecipi-
tates were adjusted to contain the same levels of Dok-1 in quantity and 
examined as in C. 
JEM VOL. 201, February 7, 2005
 
335
 
BRIEF DEFINITVE REPORT
 
Dok-1 and Dok-2 are essential adaptors in the negative 
regulation of Erk upon LPS treatment
 
To address the molecular mechanisms of the Dok-1– and
Dok-2–mediated negative regulation of LPS-evoked re-
sponses, we examined the tyrosine phosphorylation and
adaptor function in peritoneal macrophages. Antiphosphoty-
rosine immunoblot and coimmunoprecipitation analyses re-
vealed that the Dok family proteins were indeed tyrosine
phosphorylated as early as 1 min after LPS treatment and
coimmunoprecipitated with p120 rasGAP (Fig. 1 C). Inter-
estingly, Dok-1, but not Dok-2, decreased in quantity at
least 30 min after the stimulation, indicating that the bio-
chemical responses of these proteins differ. However, when
immunoprecipitated Dok-1 was adjusted to the same quan-
tity at each time point, its tyrosine phosphorylation and
binding to rasGAP was obvious even 30 min after the stimu-
lation with LPS (Fig. 1 D). These results indicate that Dok-1
and Dok-2 are adaptors involved in LPS-evoked signaling,
which activates PTK(s) to phosphorylate them, and also sug-
gest that these adaptors negatively regulate Erk upon TLR4
signaling, like in many other signaling situations downstream
of PTKs. Thus, the activation of Erk as well as JNK and p38
MAP kinase was evaluated upon LPS treatment of BM-
derived macrophages from mice lacking Dok-1 or Dok-2. Al-
though JNK and p38 MAP kinase activation was normal in
those macrophages, the activation of Erk was remarkably en-
hanced and sustained (Fig. 2 A). In addition, the phosphory-
lation and degradation of I
 
 
 
B-
 
  
 
as well as the activation of
Figure 2. Dok-1 and Dok-2 are negative regulators of Erk upon 
TLR4 signaling. (A) Total Erk, activated Erk (p-Erk), JNK (p-JNK), or p38 
MAP kinase (p-p38) was examined with immunoblotting upon LPS treat-
ment of BM-derived macrophages from mice. (B) NF- B activation was 
assessed by immunoblotting for I B  or its phosphorylation (p-I B ) 
upon LPS treatment of macrophages in A. Control immunoblotting for Erk 
was performed. (C) NF- B activity was examined by gel mobility shift assay 
upon LPS treatment of peritoneal macrophages. Positions of the NF- B 
complex and the free probes are indicated. The specificity was determined 
by adding excess amounts of unlabeled competitor of the probe (LPS   comp) 
or not (LPS) to nuclear extracts of wild-type macrophages. (D) Activated Erk 
(p-Erk), total Erk, Dok-1, or Dok-2 was examined with immunoblotting 
upon LPS treatment of RAW 264.7 cells (mock) or those expressing exoge-
nous Dok-1 (top) or Dok-2 (bottom). An arrowhead indicates the position 
of endogenous Dok-1 or Dok-2. (E) RAW 264.7 cells (mock) or those ex-
pressing exogenous Dok-1 or a Dok-1 mutant (Dok-1 YF) were examined 
as in D. (F) RAW 264.7 cells (mock) or those expressing exogenous Dok-1, 
Dok-1 YF, or Dok-2 were cultured in the presence ( ) or absence ( ) of 
LPS, and then the percentage of intracellular TNF-   cells was determined 
with flow cytometry. SD is from triplicate experiments. 
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NF-
 
 
 
B were unaffected in macrophages regardless of the
mutations (Fig. 2, B and C). Together, our findings demon-
strate that Dok-1 and Dok-2 are essential adaptors in the
negative regulation of Erk, but not JNK, p38 MAP kinase,
and NF-
 
 
 
B, upon TLR4 signaling. Moreover, that the ex-
pression levels of Dok-1 and Dok-2 were unchanged at least
early on and the phosphorylation was very rapid upon LPS
treatment indicates that both adaptors are on standby before
the onset of the signaling to be rapidly activated (Fig. 1 C).
 
Forced expression of Dok-1 or Dok-2 inhibits LPS-induced 
Erk activation and TNF-
 
  
 
production
 
To confirm that Dok-1 and Dok-2 are negative regulators of
Erk and TNF-
 
  
 
responses to LPS, we examined if forced
expression in macrophages of either adaptor suffices to in-
hibit those responses. The control RAW 264.7 macrophages
displayed an intact Erk activation, TNF-
 
  
 
production, and
Dok-1 down-regulation upon LPS treatment (Fig. 2, D–F).
However, forced expression of flag-tagged Dok-1 or Dok-2
clearly inhibited the Erk and TNF-
 
  
 
responses to LPS, indi-
cating that Dok-1 and Dok-2 are potent negative regulators
of the signaling. Note that the flag-tagged Dok-1, but not
Dok-2, was down-regulated like the endogenous Dok-1.
Recently, we identified Tyr-336 and Tyr-340 as essential
residues for Dok-1 to inhibit the Ras–Erk pathway down-
stream of Lyn (18). Consistently, forced expression of a flag-
tagged Dok-1 mutant having a Tyr/Phe substitution at these
residues (Dok-1 YF) resulted in a loss of inhibitory effects on
the LPS-evoked responses (Fig. 2, E and F). These results
strongly suggest that tyrosine phosphorylation of Dok-1 and
probably Dok-2 is essential for the inhibitory effects down-
stream of TLR4.
Although little is known about the regulation of Erk
downstream of LPS, it was reported that a MAP kinase ki-
nase kinase, Tpl2/Cot, is required for the LPS-mediated ac-
tivation of Erk in macrophages (19). The authors showed
that loss of Tpl2 specifically blocks the activation of Erk
among MAP kinases and NF-
 
 
 
B and that inhibition of
MEK, and thereby inhibition of Erk, suppressed TNF-
 
 
 
production upon LPS signaling. Moreover, it was suggested
that not only LPS but also Tpl2 requires the Ras pathway to
activate Erk (20, 21). Therefore, Ras appears to be an essen-
tial element for the activation of Erk downstream of TLR4.
Given that the Dok-1 YF mutant lacking residues essential
for the inhibition of Ras had no inhibitory effect upon
TLR4 signaling (Fig. 2, E and F), the negative signaling of
Dok-1 against Erk may intersect the Tpl2-mediated positive
signaling in the Ras pathway downstream of TLR4. Further
studies are required to understand molecular mechanisms of
the Dok-1 and Dok-2 function in the TLR4 pathway, in-
cluding the negative regulation of TNF-
 
  
 
production and
interaction with their regulators and effectors.
 
Dok-1 and Dok-2 are irrelevant to TLR9, TLR3, 
or TLR2 signaling
 
To delineate the Dok-1 and Dok-2 function in TLR-medi-
ated signaling, we examined their role upon the stimulation
of macrophages with CpG oligodeoxynucleotide (ODN) and
poly(I:C), which mimic microbial nucleotides and induce
MyD88-dependent and TRIF-dependent pathways through
TLR9 and TLR3, respectively. Interestingly, both nucle-
otides induced normal levels of Erk, JNK, and p38 MAP ki-
nase activation as well as TNF-
 
  
 
production regardless of
Dok-1 or Dok-2 mutation, indicating that both adaptors are
dispensable to the signaling downstream of these TLRs (Fig.
3, A and B, and Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20041817/DC1). Because TLR3 and
TLR9 are thought to be intracellular receptors, whereas
Figure 3. Dok-1 and Dok-2 are irrelevant to TLR9, TLR3, or TLR2 
signaling. (A–C) Activation of each MAP kinase was examined as in Fig. 2 
A upon CpG ODN, poly(I:C), or Pam3CSK4 treatment of BM-derived mac-
rophages from mice. (D) Dok-1 or Dok-2 immunoprecipitates (IP) were 
subjected to immunoblotting (IB) for Dok-1, Dok-2, or phosphotyrosine 
(PY-Dok-1 or PY-Dok-2) upon CpG ODN, poly(I:C), or Pam3CSK4 treatment 
of wild-type peritoneal macrophages for 30 min. Whole cell lysates (WCL) 
from these macrophages were subjected to immunoblotting for activated 
Erk (p-Erk) or total Erk as controls. 
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TLR4 is present on the cell surface (22), we further examined
the role of Dok-1 and Dok-2 upon the stimulation of mac-
rophages with Pam
 
3
 
CSK
 
4
 
, which is an analogue of bacterial
outer membrane lipoproteins and activates the MyD88-
dependent pathway through a cell surface receptor, TLR2.
However, Pam
 
3
 
CSK
 
4 
 
induced normal levels of MAP kinase
activation and TNF-
 
  
 
production regardless of Dok-1 or
Dok-2 mutation, indicating that both adaptors are dispens-
able to TLR2 signaling (Fig. 3 C and Fig. S2). Consistently,
CpG-ODN, poly(I:C), or Pam
 
3
 
CSK
 
4 
 
treatment did not in-
duce tyrosine phosphorylation of Dok-1 and Dok-2 or
down-regulation of Dok-1, indicating that these adaptors are
irrelevant to TLR9, TLR3, or TLR2 signaling (Fig. 3 D).
Together, Dok-1 and Dok-2 are essential adaptors for the
negative regulation of Erk specifically upon LPS treatment,
likely because LPS, but not CpG ODN, poly(I:C), or
Pam
 
3
 
CSK
 
4
 
, induces their tyrosine phosphorylation.
 
Mice lacking Dok-1 or Dok-2 are hypersensitive to LPS
 
Our in vitro and ex vivo findings suggest that mice lacking
Dok-1 or Dok-2 are hypersensitive to LPS; therefore, we
examined TNF-
 
  
 
production upon i.p. administration of
LPS to such mutant mice. Because overproduction of TNF-
 
 
 
due to excessive inflammatory responses to LPS is a cause
of endotoxin shock or lethality, we also examined the sur-
vival of LPS-injected mice. As expected, the serum concen-
tration of TNF-
 
  
 
was increased three- to fourfold in mice
lacking Dok-1 or Dok-2 as early as 1 h after injection as
compared with the wild-type controls (Fig. 4 A). Consis-
tently, the mutant mice displayed severe responses to LPS
injection at a dose sublethal to the wild-type controls (Fig. 4
B). These results demonstrate that Dok-1 and Dok-2 are
negative regulators of innate immunity, at least in the early
inflammatory responses to LPS in vivo. Because the Dok-1
or Dok-2 deficiency did not influence TNF-
 
  
 
receptor–
mediated activation of MAP kinases and NF-
 
 
 
B in perito-
neal macrophages (unpublished data), such a mutation causes
hypersensitivity to LPS, but not to TNF-
 
  
 
induced by LPS.
It is of note that augmented production of NO, another
cause of septic shock (23), was seen in macrophages lacking
Dok-1 or Dok-2 (Fig. 1 B).
The recognition of microbial pathogens by cognate
TLRs triggers the innate immune response. TLR-mediated
signaling involves at least four crucial adaptors, MyD88,
TRIF, TIRAP/Mal, and TRAM, having a Toll IL-1 recep-
tor domain, which has the capability to bind an appropriate
Toll IL-1 receptor domain in the cytoplasmic region of
TLR(s) (24). Recent studies demonstrated that TIRAP and
TRAM are essential for TLR4 to recruit MyD88 and TRIF,
respectively (25–27). TLR2 also requires TIRAP to recruit
MyD88. IRAK-M is a negative regulator of the MyD88-
dependent pathway forming a complex with IRAK and
IRAK4 to prevent phosphorylation of IRAK and its dissoci-
ation from the MyD88–TLR complex, thereby inhibiting
NF-
 
 
 
B activation (8). MyD88s acts similarly by blocking the
access of IRAK-4 to IRAK (28), and ST2 sequestrates
MyD88 and TIRAP from TLR signaling (7). Although
these negative regulators play important roles in LPS-medi-
ated signaling in macrophages, there is an inevitable lag pe-
riod for their induction upon LPS treatment of TLR4 as
mentioned earlier. Here, we demonstrated that Dok-1 and
Dok-2 are expressed at functional levels before LPS treat-
ment and thus on standby to negatively regulate Erk imme-
diately after the onset of TLR4 signaling. Interestingly, these
adaptors are irrelevant to TLR2, TLR3, and TLR9, indicat-
ing the specificity of Dok-1 and Dok-2 to TLR4 signaling
evoked by LPS, the most potent stimulator in innate immu-
nity. Because TLR2 or TLR9 triggers the MyD88-depen-
dent pathway and TLR3 triggers the TRIF-dependent path-
way, each pathway does not suffice to induce the negative
function of these adaptors. Although studies are underway to
clarify the molecular basis for the Dok-1– and Dok-2–medi-
Figure 4. Mice lacking Dok-1 or Dok-2 are hypersensitive to LPS. 
(A) Serum concentration of TNF-  of 8-wk-old mice at 1 h after injection 
(1 hpi) with LPS to the peritoneal cavity or before it (0 hpi) was examined 
with ELISA and shown with SD (n   7–13). The maximal p-value com-
pared with the wild-type is indicated. (B) Mice at 8 wk of age (n   13 for 
each) were injected with LPS as in A and monitored up to 7 d. Data repre-
sentative of duplicate experiments are shown. 
ROLE OF DOK-1 AND DOK-2 IN TLR4 SIGNALING | Shinohara et al.
 
338
 
ated signaling, our findings, at the very least, provide a novel
target for controlling the innate immune response.
 
MATERIALS AND METHODS
 
Reagents, mice, and cells.
 
LPS purified from 
 
Escherichia coli
 
 0111:B4
(Sigma-Aldrich), poly(I:C) (Amersham Biosciences), CpG ODN (5
 
 
 
-TCC-
ATGACGTTCCTGATGCT-3
 
 
 
; QIAGEN), and Pam
 
3
 
CSK
 
4 
 
(EMC mi-
crocollections) were purchased. The generation of Dok-1 or Dok-2 KO
mice was described (14, 15), and these mice were backcrossed to C57BL/6
for at least eight generations. Mice were kept under specific pathogen-free
conditions and subjected to experiments at 8–12 wk of age. Experiments
and animal care were performed according to institutional guidelines. Peri-
toneal exudate cells (PECs) were collected with 2 mM EDTA/PBS 3 d af-
ter an i.p. injection of 0.5 ml of 3% thioglycollate (Nissui). Resident PECs
were obtained by the same procedure without a thioglycollate injection.
These cells were washed and resuspended in DMEM containing 15% FCS.
After several hours of incubation in culture plates, adherent PECs and resi-
dent PECs were used as peritoneal macrophages and peritoneal resident
macrophages, respectively. BM cells were cultured in DMEM containing
10 ng/ml of murine M-CSF (PeproTech) and 15% FCS. After 7 d of cul-
ture, adherent cells were maintained in the absence of M-CSF for 24 h and
used as BM-derived macrophages. RAW 264.7 cells were cultured in
DMEM containing 15% FCS.
 
Flow cytometry.
 
A single cell suspension of peritoneal resident or RAW
264.7 macrophages was treated with 10 or 1.0 
 
 
 
g/ml LPS, respectively, and
2.0 
 
 
 
g/ml brefeldin A (Sigma-Aldrich) for 16 h, and then the former cells
were stained with PE-conjugated mAbs to CD11b (BD Biosciences). Intra-
cellular TNF-
 
  
 
was stained with a CytoStain kit (BD Biosciences), and flow
cytometry was performed with a FACSCalibur (Becton Dickinson). Data
representative of quintuplicate experiments are shown (refer to Fig. 1 A).
 
NO production assay.
 
To evaluate NO production, cells were cultured
for 24 h and the NO
 
2
 
  
 
concentration in the medium was measured with a
NO
 
2
 
/NO
 
3 
 
Assay kit-CII (Dojindo).
 
Immunoprecipitation and immunoblotting.
 
Cells treated with 1.0 or
2.0 
 
 
 
g/ml LPS, 10  M CpG ODN, 100  g/ml poly(I:C), or 100 ng/ml
Pam3CSK4 were solubilized in 1.0% NP-40–based TNN buffer (18). For
immunoprecipitation, cell lysates were cleared and incubated with antibod-
ies to mouse Dok-1 (A3) or Dok-2 (M20; Santa Cruz Biotechnology, Inc.)
followed by incubation with protein G–Sepharose (Amersham Biosciences).
The immune complex was washed and collected as immunoprecipitates.
For immunoblotting, immunoprecipitates or cleared cell lysates were sepa-
rated by SDS-PAGE and transferred to PVDF membrane (Bio-Rad Labo-
ratories), which was then incubated with antibodies to phospho-ERK
(Thr202/Tyr204), phospho-p38 (Thr180/Tyr182), phospho–I B-  (Cell
Signaling), phospho-JNK (Thr183/Tyr185), ERK, I B- , Dok-2 (H192),
p120 rasGAP (Santa Cruz Biotechnology, Inc.), or phosphotyrosine (4G10;
Upstate Biotechnology), followed by incubation with secondary horse rad-
ish peroxidase–labeled (Amersham Biosciences) or AP-labeled (Santa Cruz
Biotechnology, Inc.) antibodies. The blots were visualized with the ECL
system (Amersham Biosciences) or BCIP/NBT system (Promega). Data
representative of triplicate experiments are shown.
Gel mobility shift assay. The nuclear extracts of cells treated with 1.0
 g/ml LPS were incubated with a specific probe for the NF- B DNA bind-
ing site, electrophoresed, and visualized by autoradiography as described pre-
viously (29). Data representative of triplicate experiments are shown.
Forced expression of Dok-1, Dok-1 YF, or Dok-2 in RAW 264.7
cells. cDNA for mouse Dok-1, Dok-1 YF, or Dok-2 fused with the flag tag
at the COOH terminus was generated by PCR. Each cDNA and the IRES-
GFP fragment were appropriately inserted into the mammalian expression
vector pA-puro (30). The expression plasmid was confirmed by sequencing
and transfected into RAW 264.7 cells with FuGENE 6 (Roche). The puro-
mycin-resistant clones were further selected for Dok-1 or Dok-2 expression.
ELISA. The serum TNF-  concentration of mice at 1 h after injection
with LPS (25 mg per weight kg) to the peritoneal cavity or before it, was
measured with an ELISA kit (Biosource International).
Statistical analysis. Statistical analysis was performed with Student’s t test
and analyzed using Microsoft Excel Software.
Online Supplemental Material. Fig. S1 shows normal expression of LPS
receptors on macrophages from mice lacking Dok-1 or Dok-2. Fig. S2
shows normal TNF-  production upon stimulation of TLR9, TLR3, or
TLR2 of these macrophages. Figs. S1 and S2 are available at http://
www.jem.org/cgi/content/full/jem.20041817/DC1.
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